GI CANCERS

Shared insight into the latest developments in immunotherapy and novel treatment options for colorectal cancer, including ongoing trials and the pursuit of new targets to enhance the immune response against cancer.

Tracy Proverbs-Singh, MD, and Steven Lee-Kong, MD, explore the forefront of colorectal cancer treatment, featuring targeted therapies, immunotherapy options, and the power of multidisciplinary teamwork.

The safety run-in of the LEAP-014 trial showed acceptable toxicity and antitumor responses in patients with metastatic esophageal cancer receiving pembrolizumab, lenvatinib, and chemotherapy consisting of cisplatin plus either paclitaxel or 5-fluororacil.

The addition of pembrolizumab to trastuzumab plus chemotherapy improved progression-free survival in the first-line for patients with metastatic HER2-positive gastric or gastroesophageal junction cancer.

The addition of durvalumab to standard-of-care chemotherapy shows potential to improve downstaging in patients with resectable gastroesophageal junction and gastric cancer, according to findings from the phase 3 MATTERHORN study.

New data from the phase 3 RATIONALE 305 trial of tislelizumab with chemotherapy show potential of the combination for patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma.

Expert perspectives on comprehensive treatment strategies for metastatic colorectal cancer, including systemic therapies, precision medicine, and the potential for cure.

Interim results from a phase 2 trial shows LSAM-PTX may provide therapeutic benefits for patients with locally advanced pancreatic cancer.

In the first comprehensive study of patients with pancreatic cancer treated with either MRI-guided radiotherapy or CT-guided radiotherapy, experts state MRI-guided treatment may be safer.

Focused conversation on precision medicine, including MMR testing, advanced treatment options, and the potential for non-surgical approaches in gastrointestinal malignancies.

Tracy Proverbs-Singh, MD, and Steven Lee-Kong, MD, discuss recent updates in the management of gastrointestinal malignancies, with a focus on colorectal cancer and the crucial role of precision medicine in guiding treatment decisions.

Further development of 177Lu-satoreotide tetraxetan is expected after promising data from a phase 1/2 trial were recently published.

Phase 2 studies are investigating BDC-1001 in HER2-positive gastroesophageal, colorectal, breast, and endometrial cancers.

Zev A. Wainberg, MD, discusses the pressing relevance of the outcomes of the NAPOLI 3 trial, which were presented at the 2023 Gastrointestinal Cancers Symposium.

An MCGN drug combination shows potential to be more effective than standard chemotherapy alone for treatment-naïve metastatic pancreatic cancer.

In an interview, Mohamad Adham Salkeni, MD, FRCPC, discussed the ongoing study of maintenance ivaltinostat plus capecitabine or capecitabine monotherapy in patients with metastatic pancreatic adenocarcinoma whose disease has not progressed on first-line FOLFIRINOX.

The Independent Data Safety Monitoring Committee for the phase 2 ASCEND trial has given the okay to continue evaluation of LSTA1 for patients with pancreatic cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, David Zhen, MD, explored treatment options for patients with advanced HER2-negative upper gastrointestinal cancers.

Immune checkpoint inhibitors are approved for dMMR/MSI-H gastrointestinal cancer treatment; however, approximately half of patients with dMMR/MSI-H gastrointestinal cancer exhibit primary resistance to them.

Based on the largest clinical trial of patients with HER2-amplified biliary tract cancer, a novel anti-HER bispecific antibody may be the next option.

Early clinical trial in gastrointestinal and brain cancers aim to better understand the safety and efficacy of CEND-1-targeted therapy and develop a novel CEND-1 agent.

The phase 2b VIRAGE study evaluating the combination of VCN-01 with standard-of-care chemotherapy in patients with pancreatic cancer remains on track to be fully-enrolled in the first quarter of 2024.

A promising disease control rate and overall response rate was seen with elraglusib when given with chemotherapy for patients with pancreatic cancer, according to phase 2 study findings.

According to data from the primary and updated analyses of the phase 2 DESTINY-Gastric02 study, trastuzumab deruxtecan is beneficial for patients with HER2-positive advanced gastric cancer.

Rohit Gosain, MD, and Rahul Gosain, MD, provide a summary of the key gastrointestinal cancer data updates discussed following the 2023 ASCO Annual Meeting.

The Oncology Brothers, joined by Muhammad Shaalan Beg, MD, share their thoughts on data from the IMbrave050 trial investigating adjuvant atezolizumab plus bevacizumab in patients with high-risk hepatocellular carcinoma.

A review of recent data from NAPOLI-3 comparing the NALIRIFOX chemotherapy regimen versus nab-paclitaxel plus gemcitabine for patients with metastatic pancreatic ductal adenocarcinoma.

Expert oncologists review recent data from the NORPACT-1 study on the use of neoadjuvant FOLFIRINOX chemotherapy for patients with resectable pancreatic head cancer.

Muhammad Shaalan Beg, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent data from the PROSPECT trial investigating neoadjuvant therapy regimens for the treatment of locally advanced rectal cancer.

Interim analysis results of the phase 3 PANOVA-3 trial in patients with unresectable, locally advanced pancreatic cancer support the company proceeds with the final analysis